Emerging concepts and therapies for chronic obstructive pulmonary disease

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 6, 2013, Pages 303-308

  Raghavan, Natya ^a   McIvor, R Andrew ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease; Exacerbations; Phenotypes; Spirometry

Indexed keywords

ACLIDINIUM BROMIDE; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; VILANTEROL; ANTIINFECTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COMORBIDITY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DYSPNEA; FORCED EXPIRATORY FLOW; FRACTURE; HEARING IMPAIRMENT; HUMAN; INHALER; MEDICAL RESEARCH; PATIENT CARE; PHENOTYPE; PNEUMONIA; PROCESS OPTIMIZATION; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING; INHALATIONAL DRUG ADMINISTRATION; PERSONALIZED MEDICINE; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; HUMANS; INDIVIDUALIZED MEDICINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84883012800     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1776     Document Type: Review

References (36)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013 Update. http://www.goldcopd.com. Accessed April 20, 2013.
2. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009; 34: 648-654.
3. Jones PW, Brusselle G, Dal Negro RW, et al. Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J. 2011; 38: 29-35.
4. Raghavan N, Lam YM, Webb KA, et al. Components of the COPD Assessment Test (CAT) associated with a diagnosis of COPD in a random population sample. COPD. 2012; 9: 175-183.
5. Hurst JR, Vestbo J, Anzueto A, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363: 1128-1138.
6. Suissa S, Dell'Aniello S, Ernst P. Long-Term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67: 957-963.
7. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374: 685-694.
8. Leigh R, Pizzichini MM, Morris MM, et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006; 27: 964-971.
9. Liesker JJ, Bathoorn E, Postma DJ, et al. Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. Respir Med. 2011; 105: 1853-1860.
10. Regan EA, Hokanson JE, Murphy JR, et al. Genetic Epidemiology of COPD (COPDGene) Study Design. COPD. 2010; 7: 32-43.
11. Kim DK, Cho MH, Hersh CP, et al.; ECLIPSE, ICGN, and COPDGene Investigators. Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186: 1238-1247.
12. Vestbo J, Edwards LD, Scanlon PD, et al.; ECLIPSE Investigators. Changes in Forced Expiratory Volume in 1 Second over Time in COPD. N Engl J Med. 2011; 365: 1184-1192.
13. D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-To-severe COPD: the GLOW1 trial. Respir Res. 2011; 12: 156.
14. Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-To-severe COPD over 52 weeks: The GLOW2 study. Eur Respir J. 2012; 40: 1106-1114.
15. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012; 7: 503-513.
16. Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011; 12: 55.
17. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012; 40: 830-836.
18. Fuhr R, Magnussen H, Sarem K, et al. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest. 2012; 141: 745-752.
19. Kerwin EM, Williams J. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective. Ther Adv Respir Dis. 2013; 7: 25-37.
20. Donohue JF, Charles Fogarty C, Lotvall J, et al.; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010; 182: 155-162.
21. van Noord JA, Buhl R, LaForce C, et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 2010; 65: 1086-1091.
22. Van de Maele B, Fabbri LM, Martin C, et al. Cardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patients. COPD. 2010; 7: 418-427.
23. Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax. 1998; 53: 477-482.
24. Calverley PM, Anderson JA, Celli B, et al.; TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356: 775-789.
25. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013; 1: 210-223.
26. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol or fluticason-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007; 146: 545-555.
27. Gaebel K, McIvor RA, Xie F, et al. Triple therapy for the management of COPD: a review. COPD. 2011; 8: 206-243.
28. Albert RK, Connett J, Bailey WC, et al.; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011; 365: 689-698.
29. Pomares X, Montón C, Espasa M, et al. Long-Term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis. 2011; 6: 449-456.
30. Mammen MJ, Sethi S. Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease. Pol Arch Med Wewn. 2012; 122: 54-59.
31. Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med Princ Pract. 2010; 19: 330-338.
32. Qian J, Simoni-Wastila L, Langenberg P, et al. Effects of depression diagnosis and antidepressant treatment on mortality in medicare beneficiaries with chronic obstructive pulmonary disease. J Am Geriatr Soc. 2013; 61: 745-761.
33. Qian J, Simoni-Wastila L, Rattinger GB, et al. Association between depression and maintenance medication adherence among Medicare beneficiaries with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry. 2013 Apr 19. E-pub ahead of print].
34. Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010; 65: 956-962.
35. Rocker G, Young J, Donahue M, et al. Perspectives of patients, family caregivers and physicians about the use of opioids for refractory dyspnea in advanced chronic obstructive pulmonary disease. CMAJ. 2012; 184: E497-504.
36. Young J, Donahue M, Farquhar M, et al. Using opioids to treat dyspnea in advanced COPD: attitudes and experiences of family physicians and respiratory therapists. Can Fam Physician. 2012; 58: 401-407.